Sciety arranges two private placements
Sciety is currently capitalizing a Phase II pharmaceutical company and a DNA sequencing tech company––both via private placements. The companies operate in high growth markets and raise new capital to achieve product development goals that will lead to acquisition within the next twenty-four months.
Drug candidate with a first-in-class potential
The pharmaceutical company has successfully completed Phase 1 clinical studies and is now raising new capital to initiate Phase II studies. The company is developing a drug candidate for a life-threatening disease for which there is currently no sufficient treatment.
”Over the past year, Sciety has received many requests to finance pharmaceutical companies. With a clear trajectory to the market and major commercial potential, these companies are of interest to many investors. The pharmaceutical company now being financed has already reached Phase II with a candidate that has the potential to become first-in-class,” says Andreas Lindblom, CEO of Sciety.
Since its inception, Sciety has analysed a number of pharmaceutical companies requesting its services. The first pharmaceutical company was financed last autumn and, in conjunction with this, Sciety expanded its team with one researcher from Karolinska Institute.
Sequencing creates new opportunities in research and diagnostics
This biotech company operates within DNA sequencing and is developing a solution with significantly improved performance compared with current technologies. The sequencing market is growing rapidly in terms of both research and clinical applications.
”Sciety previously financed the software company 1928 Diagnostics whose solution for the correct use of antibiotics is based on sequencing, and Cartana–– a company active in sequencing tissue samples. DNA sequencing is, without a doubt, an interesting field in which the application areas are rapidly expanding in pace with technological developments”, notes Andreas Lindblom.
Technological advances that enable the analysis of the DNA of individual cells was announced the “Breakthrough of the Year 2018” by the journal Science.
Sequencing of cells enables initiatives such as the Human Cell Atlas where all cells in the human body are mapped, which creates completely new opportunities to understand disease development, aging and other processes in the human body.
Sequencing is also expected to be used in diagnostics to an ever greater degree. One example is the company Grail, which, with Jeff Bezos and Bill Gates as financers, is developing a solution for early detection of cancer using large amounts of sequenced DNA.
Capitalisation of the companies via private placements
The companies will carry out private placements with Sciety during February and March in order to achieve product development goals that enable acquisitions within a couple of years.
If you would like to receive more information, you are most welcome to contact us.
Do you want to receive news from Sciety directly to your inbox? Subscribe here.